• Home
  • LONG-TERM SAFETY AND TOLERABILITY OF ACORAMIDIS (AG10) IN SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: UPDATED ANALYSIS FROM AN ONGOING PHASE 2 OPEN-LABEL EXTENSION STUDY.

LONG-TERM SAFETY AND TOLERABILITY OF ACORAMIDIS (AG10) IN SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: UPDATED ANALYSIS FROM AN ONGOING PHASE 2 OPEN-LABEL EXTENSION STUDY.

Author List
Ahmad Masri, Mandar Aras, Rodney H. Falk, Martha Grogan, Daniel Jacoby, Daniel P. Judge, Sanjiv Jayendra Shah, Ronald Witteles, Alan X. Ji, Paul W. Wong, Xiaofan Cao, Rebecca Vanlandingham, Leonid Katz, Uma Sinha, Jonathan C. Fox, Mathew S. Maurer
Publication
Journal of the American College of Cardiology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/344527312
Publication Year
2022
Publication Title
Ahmad Masri, Mandar Aras, Rodney H. Falk, Martha Grogan, Daniel Jacoby, Daniel P. Judge, Sanjiv Jayendra Shah, Ronald Witteles, Alan X. Ji, Paul W. Wong, Xiaofan Cao, Rebecca Vanlandingham, Leonid Katz, Uma Sinha, Jonathan C. Fox, Mathew S. Maurer. LONG-TERM SAFETY AND TOLERABILITY OF ACORAMIDIS (AG10) IN SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: UPDATED ANALYSIS FROM AN ONGOING PHASE 2 OPEN-LABEL EXTENSION STUDY. Journal of the American College of Cardiology. 2022 Mar 1; 79(9):227.